Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study.

Imoro Zeba Braimah Ernest KenuKwesi N Amissah-ArthurStephen AkafoKwaku Oppong KwartengWinfried M Amoaku

Published in: PloS one (2019)

IVZ at 1.25mg and 2mg had similar safety profiles, and did not have any major unexpected adverse events. Further studies with larger cohorts are required to confirm efficacy.

Keyphrases

double blind
clinical trial
placebo controlled
diabetic retinopathy
randomized controlled trial
study protocol
age related macular degeneration
open label
optical coherence tomography
phase iii
optic nerve